Avantor | VWR

uPA Inhibitor II, solid

Description: A cell-permeable oxazolidinone-carboxamidine compound that acts as a potent, selective, and active-site targeting inhibitor of urokinase-type plasminogen activator

Catalog Number: CAAAJ64874-MB

Supplier: Thermo Scientific Chemicals

Certificates Sale

Clearance

Anti-UPA Rabbit Polyclonal Antibody

Description: PLAU(Urokinase-type plasminogen activator) is also named as uPA and belongs to the peptidase S1 family.UPA initiates a proteolytic cascade, which degrades extracellular matrix during tissue growth and remodelling.The secreted proform of UPA is activated after binding to a specific high affinity cell surface receptor. Secreted UPA is exposed to rapid inactivation in the pericellular space by plasminogen activator inhibitor-1 (PAI-1), which is stored in the extracellular matrix bound to vitronectin.It has 2 isoforms produced by alternative splicing.Defects in PLAU are the cause of Quebec platelet disorder (QPD).

Catalog Number: 10096-798

Supplier: Proteintech

Sale

Clearance

Human Recombinant PAI2 (from E. coli)

Description: PAI-2 is an inhibitory serpin expressed mainly in keratinocytes, activated monocytes, and placental trophoblasts. It exists predominantly as a 47 kDa nonglycosylated intracellular protein which can be induced to be secreted as 60 kDa glycoprotein. The physiological relevance of this property, which is neither a consequence of any mutation in the PAI-2 gene nor associated with any known disorder, is still unclear. However, it appears that the formation of intracellular dormant polymers may be important for the controlled release of the inhibitor from PAI-2 producing cells. Plasma levels of PAI-2 are usually low or undetectable, except during pregnancy and in some forms of monocytic leukemia. Secretion of PAI-2 from the placenta normally occurs during the third trimester of pregnancy and accounts for the dramatic increase in PAI-2 levels (up to 250 ng/mL), which are maintained at these levels until postpartum, and then rapidly decline. In addition to its vital role in protecting the placenta from degradation by uPA and/or uPA-activated proteases, PAI-2 has been shown to be essential for the prevention of metastatic spread of neck, lung and breast cancers. The beneficial effect of PAI-2 seen in these studies is presumed to stem from its ability to inhibit uPA-dependent cell dissemination. PAI-2 has also been reported to inhibit keratinocyte proliferation, and to participate in the innate immune response during viral infection. Recombinant human PAI-2 is a 415-residue nonglycosylated protein.

Catalog Number: 10072-644

Supplier: Prosci

Sale

Clearance

Human Recombinant PAI-2 (from E. coli)

Description: PAI-2 is an inhibitory serpin expressed mainly in keratinocytes, activated monocytes, and placental trophoblasts. It exists predominantly as a 47 kDa, nonglycosylated, intracellular protein, which can be induced to be secreted as 60 kDa glycoprotein. The glycosylated and unglycosylated forms of PAI-2 are equally effective as inhibitors of urokinase-type plasminogen activator (uPA), the only established physiological target of this serpin. PAI-2 has a unique ability to form dormant polymers spontaneously and reversibly under physiological conditions. The physiological relevance of this property, which is neither a consequence of any mutation in the PAI-2 gene nor associated with any known disorder, is still unclear. However, it appears that the formation of intracellular, dormant polymers may be important for the controlled release of the inhibitor from PAI-2 producing cells. Plasma levels of PAI-2 are usually low or undetectable, except during pregnancy and in some forms of monocytic leukemia. Secretion of PAI-2 from the placenta normally occurs during the third trimester of pregnancy, and accounts for the dramatic increase in PAI-2 levels (up to 250 ng/ml), which are maintained at these levels until postpartum, and then rapidly decline. In addition to its vital role in protecting the placenta from degradation by uPA and/or uPA-activated proteases, PAI-2 has been shown to be essential for the prevention of metastatic spread of neck, lung and breast cancers. The beneficial effect of PAI-2 seen in these studies is presumed to stem from its ability to inhibit uPA-dependent cell dissemination. PAI-2 has also been reported to inhibit keratinocyte proliferation, and to participate in the innate immune response during viral infection. Recombinant Human PAI-2 is a 46.5 kDa, nonglycosylated protein of 415 residues.

Catalog Number: 10779-400

Supplier: Peprotech

Sale

Clearance

Anti-SERPINE1 Rabbit Polyclonal Antibody

Description: PAI1 (plasminogen activator inhibitor 1) is originally cloned from human endothelial cell (Pannekoek 1986, Ginsburg 1986) and rat hepatoma cell 3 cDNA libraries. As a member of the serpin family of serine protease inhibitors, PAI1 inhibits both tissue type palsminogen activator (tPA) and urokinase type plasminogen activator (uPA). High PAI1 levels are associated with an increased risk of thromboembolic disease while PAI1 deficiency may represent an inherited autosomal recessive bleeding disorder.

Catalog Number: 10098-364

Supplier: Prosci

Sale

Clearance

Human Recombinant Serpin E2 (from HEK293 Cells)

Description: SERPINE2 is also known as Glia-derived nexin (GDN), Peptidase inhibitor 7 (PI7), Protease nexin 1(PN1). SERPINE2 is a secreted glycoprotein which belongs to the serpin family. SerpinE1 is the primary physiological inhibitor of the two plasminogen activators urokinase (uPA) and tissue plasminogen activator (tPA). PAI-1 / GDN is also implicated in adipose tissue development. It suggests that PAI-1 inhibitors serve in the control of atherothrombosis. Defects in Serpin E1 / PN1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency) which is characterized by abnormal bleeding due to SerpinE1 defect in the plasma.

Catalog Number: 10798-350

Supplier: Prosci

Sale

Clearance

Anti-PAI1 Rabbit Polyclonal Antibody

Description: SERPINE1, also named as Plasminogen activator inhibitor type 1 (PAI-1), is a member of the serine protease inhibitor (SERPIN) superfamily. PAI-1 is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), and hence is an inhibitor of fibrinolysis. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia. In western blotting, we got two bands 55 kDa and 110 kDa, and we are unsure as to the identity of the extra 110 kDa band.

Catalog Number: 10091-746

Supplier: Proteintech

Sale

Clearance

Anti-SERPINE1 Rabbit Polyclonal Antibody (Biotin)

Description: PAI1 (plasminogen activator inhibitor 1) is originally cloned from human endothelial cell (Pannekoek 1986, Ginsburg 1986) and rat hepatoma cell 3 cDNA libraries. As a member of the serpin family of serine protease inhibitors, PAI1 inhibits both tissue type palsminogen activator (tPA) and urokinase type plasminogen activator (uPA). High PAI1 levels are associated with an increased risk of thromboembolic disease while PAI1 deficiency may represent an inherited autosomal recessive bleeding disorder.

Catalog Number: 10098-366

Supplier: Prosci

Sale

Clearance

Anti-SERPINE2 Rabbit Polyclonal Antibody

Description: SERPINE2 also called protease nexin-1 or glial-derived neurite promoting factor, is a member of the serine protease inhibitor (SERPIN) superfamily. It would be a potent inhibitor of the urokinase-plasminogen activator (uPA), tissue-type PA (tPA), thrombin, trypsin, factor Xia, and prostasin. SERPINE2 is widely expressed in various tissues, including endothelial cells, fibroblasts, smooth muscle cells, tumor cells, glial cells, neurons, and placental cells.

Catalog Number: 10093-568

Supplier: Proteintech

Sale

Clearance

Human Recombinant Serpin A5 (from Cells)

Description: Serpin A5 is a member of the human Serpin superfamily consists of at least 35 members. It is synthesized in the liver and has been detected in saliva, cerebral spinal fluid, amniotic fluid, tears and semen. As a potent inhibitor of the protein C anticoagulant pathway at the levels of both zymogen activation and enzyme inhibition, Serpin A5 additionally inhibits a variety of serine protease including thrombin, factor Xa, several kallekreins and acrosin. It plays a critical role in the processes of blood of blood coagulation and fertilization. Serpin A5 also inhibits urinary plasminogen activator (uPA), a mediator of tumor cell invasion, and regulates tumor growth and metastasis by inhibiting angiogenesis. Furthermore, recent studies have identified PCI as a potent and direct inhibitor of activated HGFA (hepatocyte growth factor activator), suggesting a novel function in the regulation of tissue repair and regeneration. Similar to Serpins C1 and D1, the thrombin inhibitory activity of serpinA5 is enhanced by heparin.

Catalog Number: 75789-646

Supplier: Prosci

Sale

Clearance

Gabexate mesylate ≥98% (by HPLC)

Description: A competitive, reversible inhibitor of serine proteases tryptase (Ki=3.4nM), thrombin (Ki=500nM), uPA (Ki=1.3µM), plasmin (Ki=1.5µM), trypsin (Ki=2µM), factor Xa (Ki=2µM). At higher concentrations it inhibits kallikrein-1 (Ki=2.6mM), C1 esterase (IC50=520µM), as well as phospholipase A2 (IC50=500µM), rat iNOS (Ki=5mM) and cNOS (Ki=150µM), and swine kidney copper amine oxidase (Ki=27µM), but not chymotrypsin. Has been used in tissue culture and in vivo. In clinical use for pancreatitis.

Catalog Number: 89161-684

Supplier: Enzo Life Sciences

Sale